Licensing deal threatens cheap pharmaceuticals
Recommend on Google+
Excellent article to discussing development economics, barriers to growth, entry and trade agreements.
The EU is preparing for trade talks with India in Brussels next week. Among the reams of small print are several clauses that seek to protect the intellectual property rights and commercial interests of European pharmaceuticals giants. If the deal is agreed, it would create a new patent-like barrier which threatens the flow of cheap, life-saving medicines to children like Stella.
The clause causing most concern is “data exclusivity”, which would effectively block Indian producers from registering copies of foreign drugs, including those not protected by the existing patents system. This would mean delays of up to 10 years in delivery of generic versions of new, improved medicines and up to 15 years in the case of paediatric versions of the same drugs.
Read more: here.
blog comments powered by Disqus
ECONOMICS TEACHER RESOURCE NEWSLETTER
Join over 6,000 other Economics Teachers in the UK and around the world who receive the tutor2u regular Economics Resource Email Newsletter. Get special offers, first news of latest resources, teaching ideas, conferences and workshops + loads of great ideas for teaching economics from our blog authors.
